Skip to content
10-K

Annual Report

Lomond Therapeutics Holdings, Inc.

0001213900-25-032200

← back to feed
Filed
Apr 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Apr 15, 2025 32.2M sh
Shares Diluted restated FY 2024 · Dec 31, 2023 758.97K sh
Operating Cash Flow restated FY 2024 · Dec 31, 2023 −$8.41M
Current Liabilities restated FY 2024 · Dec 31, 2023 $856.14K
Total Liabilities restated FY 2024 · Dec 31, 2023 $856.14K
Current Assets restated FY 2024 · Dec 31, 2023 $800.73K
Total Assets restated FY 2024 · Dec 31, 2023 $800.73K
Eps Diluted restated FY 2024 · Dec 31, 2023 −$13.10
Eps Basic restated FY 2024 · Dec 31, 2023 −$13.10
Sga Expense restated FY 2024 · Dec 31, 2023 $20.64K
Rd Expense FY 2024 · Dec 31, 2023 $9.73M
Net Income restated FY 2024 · Dec 31, 2023 −$9.94M
Operating Income restated FY 2024 · Dec 31, 2023 −$9.75M
Stockholders Equity restated FY 2024 · Dec 31, 2022 −$9.72M